Findings
3448
ADVERSE EVENTS
This randomized clinical trial included 3448 patients with AIS who received GDLM or placebo injections within 48 hours after symptoms for 14 days; the proportion of patients achieving a favorable outcome, defined as the 90-day modified Rankin Scale score of 1 or 0, was 50.8% in the GDLM group, significantly higher than 44.1% in the placebo group. The rate of adverse events was similar between the 2 groups.